Human regulatory T cells in allogeneic stem cell transplantation

Ukena, Sya N.; Velaga, Sarvari; Geffers, Robert; Grosse, Jens; Baron, Udo; Buchholz, Stefanie; Stadler, Michael; Bruder, Dunja; Ganser, Arnold; Franzke, Anke

doi:10.1182/blood-2011-05-352708

Cited by 65 publications

(54 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,8,40 We and others have shown that Tregs may produce IFN-g and IL-17 when stimulated under proinflammatory conditions [9][10][11][12][13] and that these differentiated cells are found at sites of inflammation. 19,41 In our search for immunomodulatory components that influence the Treg differentiation process, we hypothesized that PMPs might constitute a relevant force.…”

Section: Discussionmentioning

confidence: 97%

Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin

Dinkla

Cranenbroek

Heijden³

et al. 2016

Blood

112

101

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin

Dinkla

Cranenbroek

Heijden³

et al. 2016

Blood

112

101

View full text Add to dashboard Cite

show abstract

“…Consistently, aberrant expression of homing receptors has been reported in a recent study comparing Tregs in patients developing or not GVHD after alloHSCT. 47 Alternatively, CD4…”

Section: Discussionmentioning

confidence: 99%

Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease

Dong

Maiella

Xhaard³

et al. 2013

Blood

View full text Add to dashboard Cite

show abstract

“…[27][28][29][30][31][45][46][47][48] As soon as T lymphocytes were detectable, at 1-month post-transplant, their content in iNKT cell was in the normal range. In the same way, the recovery of CD4 T lymphocytes is associated with a frequency of CD25 þ FOXP3 þ cells within the normal range as soon as 1-month post-transplant.…”

Section: Discussionmentioning

confidence: 99%

Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children

Charrier

Cordeiro

Brito

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Some clinical characteristics of cord blood transplantation (CBT) might be explained by specificities in the reconstitution of immune subsets differing by their maturation stage or their implication in GVHD, tolerance or immune responses against tumor or infectious agents. Here, we compare the immune reconstitution of several of these subsets after CBT and BMT. B-cell count recovery was faster after CBT. There was no difference in the recovery of CD4 þ and CD8 þ cell counts. There was no difference either in the frequency of several subsets: CD45RO þ memory, and CD45RA þ naïve cells within the CD4 þ T-cell compartment, CD27 þ among B cells, CD56 bright , NKG2A þ , and KIR þ cells among natural killer (NK) cells, CD25 þ FOXP3 þ regulatory T cells and invariant NKT cells. The proportion of the thymic naïve CD31 þ CD45RA þ CD4 þ T cells was lower after CBT at 6 months post-transplant, and was still below normal at 1 year in both groups. NK-cell expansion was more sustained after CBT, with fewer double-negative NKG2A À KIR À hyporesponsive cells and more double-positive NKG2A þ KIR þ hyper-responsive NK cells. These results, therefore, indicate that further research to improve CBT outcome should try to improve thymopoieisis and take advantage of the sustained NK-cell reconstitution. INTRODUCTIONAlmost all lethal complications of hematopoietic SCT, including leukemia relapse, and opportunistic infections, result from the post-transplant immune deficiency that lasts for months after transplantation. Therefore, the therapeutic challenge in improving the outcome for transplanted children outcome relies on the enhancement of immune reconstitution and the GVL effect, without increasing the harmful GVHD.Although lower rates of engraftment and GVHD and higher rates of life-threatening infections have been reported in patients who received cord blood transplantation (CBT), similar EFS and leukemia relapse rates have been observed after CBT and BMT. [1][2][3][4][5] These observations indicate that cord blood-derived immune cells have unique immune properties that allow for allogeneic tolerance while preserving the GVL effect.Previous studies have compared the reconstitution of the major immune cell populations after CBT and BMT: CD4 þ and CD8 þ T cells, natural killer (NK) and B cells. They showed that T-cell recovery is delayed, in particular CD8 þ T-lymphopoiesis after CBT, 2,6-9 although T-cell diversity has been shown to be similar in cord blood (CB) and BM recipients beyond 1 year after transplant. 7,10 Conversely, innate immunity recovery has been shown to be similar between CB and BM recipients, with normal cell counts of functional NK cells in the blood as soon as 1-month post-CBT. 2,11,12 Finally, B-cell number recovery appears to be faster after CBT. 6,9,13 Besides these differences in the reconstitution of the major lymphocyte populations, additional changes in the reconstitution of other immune cell subsets might occur and explain some of the clinical differences observed in patients who receive BMT or CBT.

show abstract

Human regulatory T cells in allogeneic stem cell transplantation

Cited by 65 publications

References 43 publications

Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin

Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin

Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease

Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children

Contact Info

Product

Resources

About